文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

褪黑素对COVID-19诱导性肺炎ICU患者的疗效评估:随机对照试验方案结构化摘要

Evaluation of the effect of melatonin in patients with COVID-19-induced pneumonia admitted to the Intensive Care Unit: A structured summary of a study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2021-03-08

本试验为单中心、开放标签、平行组随机对照试验,在伊朗Shahid Mohammadi医院ICU开展。计划随机纳入60例确诊COVID-19且影像学显示严重肺炎的成人患者,比较标准治疗联合褪黑素5 mg每日两次(共7天)与标准治疗的疗效。主要结局为7天内临床症状恢复率及动脉血气、C反应蛋白、铁蛋白、乳酸脱氢酶变化。

要点

  • 纳入年龄>20岁、RT-PCR或血清学确诊、影像学示严重肺炎且签署知情同意者。
  • 排除有惊厥、慢性肝肾疾病、使用机械通气、褪黑素过敏及妊娠哺乳者。
  • 干预组在伊朗卫生部标准方案上加用褪黑素5 mg每日两次,疗程7天。

核心结论

  • 该方案旨在评估褪黑素联合标准治疗对重症COVID-19肺炎ICU患者临床症状和实验室指标的影响。

研究设计与样本

  • 单中心、开放标签、平行组随机对照试验,在伊朗Shahid Mohammadi医院ICU进行。
  • 计划随机纳入60例患者,按1:1比例分为干预组30例和对照组30例。
  • 采用区组随机化(每区组6例),由网络系统生成随机数和分配隐藏。

关键数值与推荐

  • 干预组:伊朗卫生部标准COVID-19治疗方案联合褪黑素软胶囊5 mg每日两次,共7天。
  • 对照组:仅伊朗卫生部标准COVID-19治疗方案,共7天。
  • 主要结局:随机后7天内临床症状恢复率及动脉血气、C反应蛋白、铁蛋白、乳酸脱氢酶检测。
  • 次要结局:临床和副临床特征改善时间、ICU住院时长、机械通气需求及7天内死亡率。

局限性

  • 开放标签设计,无盲法和安慰剂对照。
  • 单中心研究,样本量60例,可能影响结果外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We investigate the effects of melatonin, compared to the usual therapeutic regimen on clinical symptoms and laboratory signs in severely ill patients with confirmed COVID-19 who are admitted to the Intensive Care Unit (ICU). TRIAL DESIGN: This is a single-center, open-label, randomized, clinical trial with a parallel-group design. This study is being conducted at Shahid Mohammadi Hospital, Bandar Abbas, Iran. PARTICIPANTS: All patients admitted to the ICU of Shahid Mohammadi Hospital, Bandar Abbas, Iran, will be screened for the following criteria. Inclusion criteria 1. Age >20 years 2. Definitive diagnosis of COVID-19 based on RT-PCR or/and serological testing 3. Severe pneumonia and lung involvement in imaging 4. Signing informed consent Exclusion criteria 1. Underlying diseases, including convulsive disorders, chronic hepatic and renal diseases 2. Use of mechanical ventilation 3. History of known allergy to Melatonin 4. Pregnancy and breastfeeding INTERVENTION AND COMPARATOR: Intervention group: The standard treatment regimen for COVID-19, according to the Iranian Ministry of Health and Medical Education's protocol, along with Melatonin soft gelatin capsule (Danna Pharmaceutical Company) at a dose of 5 mg twice a day for a period of seven days. CONTROL GROUP: The standard treatment for COVID-19 based on the Iranian Ministry of Health and Medical Education's protocol for a period of seven days. MAIN OUTCOMES: The primary outcomes are the recovery rate of clinical symptoms and checking arterial blood gas (ABG), C-reactive protein (C-RP), Ferritin, Lactate dehydrogenase (LDH) within seven days of randomization. The secondary outcomes are time to improvement of clinical and paraclinical features and length of stay in the ICU, need for mechanical ventilation, and mortality rate within seven days of randomization. RANDOMIZATION: Included patients will be allocated to one of the study arms using block randomization in a 1:1 ratio (each block consists of 6 patients). This randomization method ensures a balanced allocation between the arms during the study. A web-based system will generate random numbers for the allocation sequence and concealment of participants. Each number relates to one of the study arms. BLINDING (MASKING): This is an open-label trial without blinding and placebo control. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): A total of 60 participants randomizes (30 patients allocated to the intervention group and 30 patients allocated to the control group). TRIAL STATUS: The protocol is Version 1.0, February 16, 2021. Recruitment began February 28, 2021, and is anticipated to be completed by July 31, 2021. TRIAL REGISTRATION: The trial protocol has been registered in the Iranian Registry of Clinical Trials (IRCT). The registration number is " IRCT20200506047323N7 ". The registration date was February 16, 2021. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ameri A, Asadi MF, Kamali M, et al. Evaluation of the effect of melatonin in patients with COVID-19-induced pneumonia admitted to the Intensive Care Unit: A structured summary of a study protocol for a randomized controlled trial. Trials. 2021. PMID: 33685474. doi:10.1186/s13063-021-05162-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。